Intended for healthcare professionals

CCBYNC Open access

Rapid response to:


Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study

BMJ 2018; 360 doi: (Published 06 February 2018) Cite this as: BMJ 2018;360:k119

Rapid Response:

Absolute Risk Reductions for CVD, NNT, but also Number Needed for Harm (NNH) shall be reported.

The above information is missing in the article.

I think the readers have the right of getting these numbers.


Competing interests: No competing interests

17 February 2018
Jose Mario Franco de Oliveira
Associate Professor of Medicine.
Department of Medicine. Universidade Federal Fluminense.
Rua Senador Vergueiro # 2 Apt. 202. Rio de Janeiro, RJ, Brazil.